BioStock: Evaxion completes EVX-02 clinical trial recruitment

Evaxion Biotech has announced completing the recruitment for the phase I/IIa trial of one of their top programmes, EVX-02, which treats patients suffering from adjuvant melanoma. Due to very positive preliminary findings around the potential clinical benefit of EVX-02, the company is now accelerating its development programmes, increasing the prospects of commercialisation for the Danish company.

Read the full article at biostock.se:

https://www.biostock.se/en/2022/03/evaxion-completes-evx-02-clinical-trial-recruitment/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se